SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kenhott who wrote (9929)1/31/2007 2:56:28 PM
From: Icebrg  Read Replies (1) of 10280
 
Yes, they said they intend to repay the debt.


On February 14, 2000, Sepracor issued $400,000,000 in principal amount of 5% Convertible Subordinated Debentures due 2007 (the "5% Debentures"). The 5% Debentures have an annual interest of 5% and are convertible into Sepracor Common Stock at $92.38 per share.

On March 9, 2000, Sepracor issued an additional 60,000,000 in principal amount of 5% Debentures pursuant to an option granted to the initial purchaser of the 5% Debentures. Sepracor intends to use the proceeds from the sale of the 5% Debentures for its ongoing preclinical and clinical trials, expansion of sales and marketing capabilities, funding of other research and development programs, working capital and other general corporate purposes.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext